Bristol-Myers Squibb (NYSE:BMY) shares sold by Occidental Asset Management LLC

Occidental Asset Management LLC lessened its position in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 14.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,498 shares of the biopharmaceutical company’s stock after selling 1,380 shares during the period. Occidental Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $461,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have recently bought and sold shares of the company. Northwest Financial Advisors purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $27,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $34,000. VisionPoint Advisory Group LLC boosted its stake in Bristol-Myers Squibb by 300.5% in the third quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 553 shares during the period. Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at about $40,000. Finally, Wetzel Investment Advisors Inc. purchased a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at approximately $40,000. 76.41% of shares are owned by institutional investors and hedge funds.

Bristol-Myers Squibb stock rose 0.0%

Shares of Bristol-Myers Squibb stock opened at $41.53 on Friday. The firm has a market cap of $84.19 billion, a PE ratio of -13.40, a P/E/G ratio of 14.20 and a beta of 0.43. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99, and a current ratio of 1.11. The company’s 50-day moving average price is $42.97, and its two-hundred-day moving average price is $48.14. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $65.38.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. In the same quarter last year, the business earned $2.05 EPS. On average, research analysts forecast that Bristol-Myers Squibb will post 0.58 EPS for the current fiscal year.

Bristol-Myers Squibb announces dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a $0.60 dividend. The ex-dividend date of this dividend is Friday, July 5. This represents an annualized dividend of $2.40 and a yield of 5.78%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Analyst upgrades and downgrades

A number of analysts have recently commented on BMY shares. Barclays decreased their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday. BMO Capital Markets decreased their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $60.00.

Get the latest analysis on Bristol-Myers Squibb

Bristol-Myers Squibb profile

(Free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Want to see what other hedge funds BMY owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.